Effect of the Appended Morpholinyl Group on Photophysical Behavior of Mono- and Bis-cyclometalated Terpyridine Iridium(III) Chromophores

This paper provides extensive studies of [IrCl(Ph-py)(morph-C6H4-terpy-κ3N)]PF6 (1A), [Ir(Ph-py)2(morph-C6H4-terpy-κ2N)]PF6 (2A), [IrCl(Ph-py)(Ph-terpy-κ3N)]PF6 (1B), and [Ir(Ph-py)2(Ph-terpy-κ2N)]PF6 (2B) designed to demonstrate the possibility of controlling the photophysical properties of mono- and bis-cyclometalated complexes [IrCl(Ph-py)(R-C6H4-terpy-κ3N)]PF6 and [Ir(Ph-py)2(R-C6H4-terpy-κ2N)]PF6 through a remote electron-donating substituent introduced into the 4'-position of 2,2':6',2″-terpyridine (terpy) via the phenyl linker. The attachment of the morpholinyl (morph) group was evidenced to induce dramatic changes in the emission characteristics of the monocyclometalated Ir(III) systems with meridionally coordinated R-C6H4-terpy ligand (κ3N). In solution, the obtained complex [IrCl(Ph-py)(morph-C6H4-terpy-κ3N)]PF6 was found to be a rare example of dual-emissive Ir(III) systems. Within the series [Ir(Ph-py)2(R-C6H4-terpy-κ2N)]PF6 bearing the R-C6H4-terpy ligand bound to the central ion in a bidentate coordination mode, the appended electron-donating morpholinyl group induced a minor effect on the emission maximum, but it was found to be an effective tool for extending the excited-state lifetime, further prolonging with the increase of solvent polarity. The results of this work are of high significance for better understanding the push-pull effect and dual-emission phenomena in Ir-based luminophores, as well as developing chromophores with prolonged emission lifetimes.

A photo-degradable BODIPY-modified Ru(II) photosensitizer for safe and efficient PDT under both normoxic and hypoxic conditions

Photodynamic therapy (PDT) is promising for cancer treatment but still suffers from some limitations. For instance, PDT based on 1O2 generation (in a type-II mechanism) is heavily dependent on high oxygen concentrations and will be significantly depressed in hypoxic tumors. In addition, the residual photosensitizers after PDT treatment may cause severe side-effects under light irradiation. To solve these problems, herein a BODIPY (boron dipyrromethene)-modified Ru(II) complex [Ru(dip)2(tpy-BODIPY)]2+ (complex 1, dip = 4,7-diphenyl-1,10-phenanthroline, tpy = 2,2':6',2''-terpyridine) was designed and synthesized. Complex 1 exhibited both high singlet oxygen quantum yield (Φ = 0.7 in CH3CN) and excellent superoxide radical (O2˙-) generation, and thus demonstrated efficient PDT activity under both normoxic and hypoxic conditions. Moreover, complex 1 is photo-degradable in water, and greatly loses its ROS generation ability after PDT treatment. These novel properties of complex 1 make it promising for efficient PDT under both normoxic and hypoxic conditions with reduced side-effects.

A Photoactivated Ru (II) Polypyridine Complex Induced Oncotic Necrosis of A549 Cells by Activating Oxidative Phosphorylation and Inhibiting DNA Synthesis as Revealed by Quantitative Proteomics

The ruthenium polypyridine complex [Ru(dppa)₂(pytp)] (PF₆)₂ (termed as ZQX-1), where dppa = 4,7-diphenyl-1,10-phenanthroline and pytp = 4'-pyrene-2,2':6',2''-terpyridine, has been shown a high and selective cytotoxicity to hypoxic and cisplatin-resistant cancer cells either under irradiation with blue light or upon two-photon excitation. The IC₅₀ values of ZQX-1 towards A549 cancer cells and HEK293 health cells are 0.16 ± 0.09 µM and >100 µM under irradiation at 420 nm, respectively. However, the mechanism of action of ZQX-1 remains unclear. In this work, using the quantitative proteomics method we identified 84 differentially expressed proteins (DEPs) with |fold-change| ≥ 1.2 in A549 cancer cells exposed to ZQX-1 under irradiation at 420 nm. Bioinformatics analysis of the DEPs revealed that photoactivated ZQX-1 generated reactive oxygen species (ROS) to activate oxidative phosphorylation signaling to overproduce ATP; it also released ROS and pyrene derivative to damage DNA and arrest A549 cells at S-phase, which synergistically led to oncotic necrosis and apoptosis of A549 cells to deplete excess ATP, evidenced by the elevated level of PRAP1 and cleaved capase-3. Moreover, the DNA damage inhibited the expression of DNA repair-related proteins, such as RBX1 and GPS1, enhancing photocytotoxicity of ZQX-1, which was reflected in the inhibition of integrin signaling and disruption of ribosome assembly. Importantly, the photoactivated ZQX-1 was shown to activate hypoxia-inducible factor 1A (HIF1A) survival signaling, implying that combining use of ZQX-1 with HIF1A signaling inhibitors may further promote the photocytotoxicity of the prodrug.

Outsourcing Intersystem Crossing without Heavy Atoms: Energy Transfer Dynamics in PyridoneBODIPY-C60 Complexes

The excited state dynamics in two fully characterized pyridoneBODIPY-fullerene complexes were investigated using time-resolved spectroscopy. Photoexcitation was initially localized on the pyridoneBODIPY chromophore. The energy was rapidly transferred to the fullerene, which subsequently underwent ISC to form a triplet state and returned the energy to the pyridoneBODIPY via triplet-triplet energy transfer. This ping-pong energy transfer mechanism resulted in efficient (>85%) overall conversion of the excited state pyridoneBODIPY constituent despite a complete lack of ISC in the pyridoneBODIPY in the absence of the fullerene partner. The small difference in attachment chemistry for the fullerene did not impact the initial singlet energy transfer. However, the N-methylpyrrolidine bridge did slow both the triplet-triplet energy transfer and the ultimate relaxation rate of the final triplet state when compared to an isoxazole-based bridge. The rates of each step were quantified, and computational predictions were used to complement the proposed mechanism and energetics. The result demonstrated efficient triplet sensitization of a strong chromophore that lacks significant spin-orbit coupling.

Three-photon absorption iridium(iii) photosensitizers featuring aggregation induced emission

Ir-H exhibits better three-photon absorption aggregation induced emission property, and thus can enhance the photodynamic therapy efficiency.

A targeted and efficient CDT system with photocatalytic supplement of H2O2 and hydroxyl radical production at a neutral pH

The bottleneck problems of chemodynamic therapy (CDT) are the dependence on an acidic pH (2.0-4.0), insufficient H2O2 level in tumor tissues and potential systematic toxicity of inorganic nanomaterials-based CDT agents....

Bioorthogonal Assembly Based on Metallophilic Interactions for Selective Imaging and PDT Treatment of Cancer Cells

Precise control of the luminescence and singlet oxygen generation is important for selective photo-theranostics applications. In this work, bioorthogonal assembly based on d10···d10 metallophilic interactions was first proposed for selective...

Recent Strategies to Develop Innovative Photosensitizers for Enhanced Photodynamic Therapy

This review presents a robust strategy to design photosensitizers (PSs) for various species. Photodynamic therapy (PDT) is a photochemical-based treatment approach that involves the use of light combined with a light-activated chemical, referred to as a PS. Attractively, PDT is one of the alternatives to conventional cancer treatment due to its noninvasive nature, high cure rates, and low side effects. PSs play an important factor in photoinduced reactive oxygen species (ROS) generation. Although the concept of photosensitizer-based photodynamic therapy has been widely adopted for clinical trials and bioimaging, until now, to our surprise, there has been no relevant review article on rational designs of organic PSs for PDT. Furthermore, most of published review articles in PDT focused on nanomaterials and nanotechnology based on traditional PSs. Therefore, this review aimed at reporting recent strategies to develop innovative organic photosensitizers for enhanced photodynamic therapy, with each example described in detail instead of providing only a general overview, as is typically done in previous reviews of PDT, to provide intuitive, vivid, and specific insights to the readers.

Highly Efficient Ir(III)-Coumarin Photo-Redox Catalyst for Synergetic Multi-Mode Cancer Photo-Therapy

Four photo-catalysts of the general formula [Ir(CO6/ppy)₂ (L)]Cl where CO6=coumarin 6 (Ir1-Ir3), ppy=2-phenylpyridine (Ir4), L=4'-(3,5-di-tert-butylphenyl)-2,2' : 6',2''-terpyridine (Ir1), 4'-(3,5-bis(trifluoromethyl)phenyl)-2,2' : 6',2''-terpyridine (Ir2 and Ir4), and 4-([2,2' : 6',2''-terpyridin]-4'-yl)-N,N-dimethylaniline (Ir3) were synthesized and characterized. These photostable photo-catalysts (Ir1-Ir3) showed strong visible light absorption between 400-550 nm. Upon light irradiation (465 and 525 nm), Ir1-Ir3 generated singlet oxygen and induced rapidly photo-catalytic oxidation of cellular coenzymes NAD(P)H. Ir1-Ir3 showed time-dependent cellular uptake with excellent intracellular retention efficiency. Upon green light irradiation (525 nm), Ir2 provided a much higher photo-index (PI=793) than the clinically used photosensitizer, 5-aminolevulinicacid (5-ALA, PI>30) against HeLa cancer cells. The observed necro-apoptotic anticancer activity of Ir2 was due to the Ir2 triggered photo-induced intracellular redox imbalance (by NAD(P)H oxidation and ROS generation) and change in the mitochondrial membrane potential. Remarkably, Ir2 showed in vivo photo-induced catalytic anticancer activity in mouse models.

Photo-induced mitochondrial DNA damage and NADH depletion by -NO2 modified Ru(II) complexes

Two mitochondria-localized Ru(ii) complexes with photo-labile ligands were reported to exert one- and two-photon activatable anticancer activity through a dual-function mechanism, i.e. mitochondrial DNA covalent binding after photo-induced ligand dissociation and photo-catalyzed NADH depletion, thus displaying good activity towards cisplatin-resistant cancer cells under both normoxic and hypoxic conditions.

Ru(ii) and Ir(iii) phenanthroline-based photosensitisers bearing o-carborane: PDT agents with boron carriers for potential BNCT

Four novel transition metal-carborane photosensitisers were prepared by Sonogashira cross-coupling of 1-(4-ethynylbenzyl)-2-methyl-o-carborane (A-CB) with halogenated Ru(ii)- or Ir(iii)-phenanthroline complexes. The resulting boron-rich complexes with one (RuCB and IrCB) or two carborane cages (RuCB2 and IrCB2) were spectroscopically characterised, and their photophysical properties investigated. RuCB displayed the most attractive photophysical properties in solution (λ_em 635 nm, τ_T 2.53 μs, and φ_p 20.4%). Nanosecond time-resolved transient absorption studies were used to explore the ³MLCT nature of the triplet excited states, and the highest singlet oxygen quantum yields (Φ_Δ) were obtained for the mono-carborane-phenanthroline complexes (RuCB: 52% and IrCB: 25%). None of the complexes produce dark toxicity in SKBR-3 cells after incubation under photodynamic therapy (PDT) conditions. Remarkably, mono-carboranes RuCB and IrCB were the best internalised by the SKBR-3 cells, demonstrating the first examples of tris-bidentate transition metal-carborane complexes acting as triplet photosensitisers for PDT with a high photoactivity; RuCB or IrCB killed ∼50% of SKBR-3 cells at 10 μM after irradiation. Therefore, the high-boron content and the photoactive properties of these photosensitisers make them potential candidates as dual anti-cancer agents for PDT and Boron Neutron Capture Therapy (BNCT).

Recent progress in photosensitizers for overcoming the challenges of photodynamic therapy: from molecular design to application

Photodynamic therapy (PDT), a therapeutic mode involving light triggering, has been recognized as an attractive oncotherapy treatment. However, nonnegligible challenges remain for its further clinical use, including finite tumor suppression, poor tumor targeting, and limited therapeutic depth. The photosensitizer (PS), being the most important element of PDT, plays a decisive role in PDT treatment. This review summarizes recent progress made in the development of PSs for overcoming the above challenges. This progress has included PSs developed to display enhanced tolerance of the tumor microenvironment, improved tumor-specific selectivity, and feasibility of use in deep tissue. Based on their molecular photophysical properties and design directions, the PSs are classified by parent structures, which are discussed in detail from the molecular design to application. Finally, a brief summary of current strategies for designing PSs and future perspectives are also presented. We expect the information provided in this review to spur the further design of PSs and the clinical development of PDT-mediated cancer treatments.

The modification of a pyrene group makes a Ru(ii) complex versatile

A versatile Ru(ii) complex with self-reporting ligand photo-dissociation and efficient two-photon excited synergistic PACT and PDT abilities was designed and studied.

Anthryl-Appended Platinum(II) Schiff Base Complexes: Exceptionally Small Stokes Shift, Triplet Excited States Equilibrium, and Application in Triplet-Triplet-Annihilation Upconversion

Two anthryl platinum(II) N,N'-bis(3,5-di-tert-butylsalicylidene)-1,2-benzenediamine Schiff base complexes were synthesized, with the anthryl attached via its 9 position (Pt-9An) or 2 position (Pt-2An) to the platinum (Pt) Schiff base backbone. The complexes show unusually small Stokes shifts (0.23 eV), representing a very small energy loss for the photoexcitation/intersystem crossing process, which is beneficial for applications as triplet photosensitizers. Phosphorescence of the Pt(II) coordination framework (Φ_P = 11.0%) is quenched in the anthryl-containing complexes (Φ_P = 4.0%) and shows a biexponential decay (τ_P = 3.4 μs/87% and 18.2 μs/13%) compared to the single-exponential decay of the native Pt(II) Schiff base complex (τ_P = 3.7 μs). Femtosecond/nanosecond transient absorption spectroscopy suggests an equilibrium between triplet anthracene (³An) and triplet metal-to-ligand charge-transfer (³MLCT) states, with the dark ³An state slightly lower in energy (1.96 eV for Pt-9An and 1.90 eV for Pt-2An) than the emissive ³MLCT state (1.97 eV for Pt-9An and 1.91 eV for Pt-2An). Intramolecular triplet-triplet energy transfer (TTET) and reverse TTET take 4.8 ps/444 ps for Pt-9An and 55 ps/1.7 ns for Pt-2An, respectively. The triplet-state equilibrium extends the triplet-state lifetime of the complexes to 103 μs (Pt-2An) or 163 μs (Pt-9An), in comparison to the native Pt(II) complex, which shows a lifetime of 4.0 μs. The complexes were used for triplet-triplet-annihilation upconversion with perylene as the triplet acceptor. The upconversion quantum yield is up to 15%, and a large anti-Stokes shift (0.75 eV) is achieved by excitation into the singlet metal-to-ligand charge-transfer absorption band (589 nm) of the complexes (anti-Stokes shift is 0.92 eV with 9,10-diphenylanthracene as the acceptor).